ASCO 2023

2023 American Society of Clinical Oncology (ASCO) Annual Meeting – June 2-6, 2023 / Chicago, IL and Virtual

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Long-Term Safety of Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 Trial (includes PLS)

Bellmunt | Poster #4516

Avelumab as Second-Line or Later Treatment in Patients With Metastatic Merkel Cell Carcinoma: Analysis of Real-World Outcomes in France Using the CARADERM Registry and the French National Healthcare Database

Blom | Poster #9537

Retrospective Clinical Analysis of Circulating Tumor DNA (ctDNA)-Based Molecular Response (MR) and Baseline Blood-Based Tumor Mutational Burden (bTMB) for Monitoring Response in Phase 3 Trial of Bintrafusp Alfa vs Pembrolizumab Treatment of Non-Small Cell Lung Cancer (NSCLC)

Feng | Poster #9088

XRay Vision: A Phase 3 Study of Xevinapant Plus Radiotherapy (RT) for High-Risk, Cisplatin-Ineligible Patients With Resected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN) (includes PLS)

Ferris | Poster #6101

Patients With EGFR-Mutant MET-Altered NSCLC Receiving Tepotinib With an EGFR Tyrosine Kinase Inhibitor (TKI): A Case Series

Le | Poster #9070

Real-World Response Rates and Outcomes of Patients Treated With First-Line Platinum-Based Chemotherapy in Advanced Urothelial Cancer

Moon | Poster #4567

Long-Term Outcomes of Tepotinib in Patients With MET Exon 14 Skipping NSCLC From the VISION Study

Paik | Poster #9060

Estimated Net Benefit of Avelumab + Best Supportive Care (BSC) vs BSC Alone for Patients With Advanced Urothelial Carcinoma (aUC) Using a Quality-Adjusted Time Without Cancer Symptoms or Toxicity (Q-TWiST) Analysis (includes PLS)

Powles | Poster #4515

Tepotinib + Osimertinib for EGFR Mutant (EGFRm) NSCLC With MET Amplification (METamp) After First-Line (1L) Osimertinib

Tan | Poster #9021

Clinical Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer Who Received Targeted Therapy in a Real-World Setting

Yang | Poster #9051

Effect of Extended Treatment With IAP Inhibitor Xevinapant Post Radiotherapy on Efficacy and the Tumor Microenvironment in Preclinical Models

Yeung | Poster #6027

Detection of MET Amplification (METamp) in Patients With EGFR Mutant (m) NSCLC After First-Line (1L) Osimertinib

Yu | Poster #9074

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 09/24

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options: